

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The sequence in Fig. 2A does not have a SEQ ID NO.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



# SEQUENCE LISTING

<110> Allen, Keith D.  
Matthews, William  
Moore, Mark

<120> TRANSGENIC MICE CONTAINING GPRC5B-LIKE  
GENE DISRUPTIONS

<130> R-390

<140> To Be Assigned

<141> Herewith

<150> US 60/256,199

<151> 2000-12-13

<150> US 60/280,359

<151> 2001-03-29

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2870

<212> DNA

<213> Homo sapiens

<400> 1

```

aggtcgcagg cgggcgtgcg tggagcgggg gccgcggccg cgccgcagag atgtgactcg 60
ggccgaaggc cagctggagc gtcggcgctg cggggcccg ggggtcgaat gttcgtggca 120
tcagagagaa agatgagagc tcaccagggtg ctcaccttcc tcctgctctt cgtgatcacc 180
tcggtggcct ctgaaaacgc cagcacatcc cgaggctgtg ggctggacct cctccctcag 240
tacgtgtccc tgtgcgacct ggacgccatc tggggcattg tgggtggaggc ggtggccggg 300
gcgggcgccc tgatcacact gctcctgatg ctcacctec tggtgcggct gcccttcac 360
aaggagaagg agaagaagag cctgtgggc ctcacttcc tgttctctct ggggaccctg 420
ggcctctttg ggctgacgtt tgcccttcac atccaggagg acgagaccat ctgctctgtc 480
cgccgcttcc tctggggcgt cctctttgcg ctctgcttct cctgcctgct gagccaggca 540
tggcgcgctg ggaggctggt gcggcatggc acggggcccc cgggctggca gctggtgggc 600
ctggcgctgt gcctgatgct ggtgcaagtc atcatcgctg tggagtggct ggtgctcacc 660
gtgctgcgtg acacaaggcc agcctgcgcc tacgagccca tggactttgt gatggccctc 720
atctacgaca tgggtactgct tgtggtcacc ctggggctgg cctcttccac tctgtgcggc 780
aagttcaaga ggtggaagct gaacggggcc ttctctctca tcacagcctt cctctctgtg 840
ctcatctggg tggcctggat gaccatgtac ctcttcggca atgtcaagct gcagcagggg 900
gatgcctgga acgacccac ctggccatc acgctggcgg ccagcggctg ggtcttctgc 960
atcttccacg ccatccctga gatccactgc acccttctgc cagccctgca ggagaacacg 1020
cccaactact tcgacacgtc gcagcccagg atgcgggaga cggccttcca ggaggacgtg 1080
cagctgccgc gggcctatat ggagaacaag gccttctcca tggatgaaca caatgcagct 1140
ctccgaacag caggatttcc caacggcagc ttgggaaaaa gaccagtggt cagcttgggg 1200
aaaagaccca gcgctccgtt tagaagcaac gtgtatcagc caactgagat ggccgctcgtg 1260
ctcaacggtg ggaccatccc aactgctccg ccaagtcaca caggaagaca cctttggtga 1320
aagactttaa gttccagaga atcagaattt ctcttaccga tttgcctccc tggctgtgtc 1380
tttcttgagg gagaaatcgg taacagttgc cgaaccaggc cgctcacag ccaggaaatt 1440
tggaaatcct agccaagggg atttctgtga aatgtgaaca ctgacgaact gaaaagctaa 1500
caccgactgc ccgccctcc cctgccacac acacagacac gtaataccag accaacctca 1560
atccccgcaa actaaagcaa agctaattgc aaatagtatt aggctcactg gaaaatgtgg 1620
ctgggaagac tgtttcatcc tctgggggta gaacagaacc aaattcacag ctggtggggc 1680
agactggtgt tggttggagg tggggggctc ccactcttat cacctctccc cagcaagtgc 1740
tggaacccag gtagcctctt ggagatgacc gttgcgttga ggacaaatgg ggactttgcc 1800

```



```

accggcttgc ctggtggttt gcacatttca ggggggtcag gagagttaag gaggttgtgg 1860
gtgggattcc aaggtgaggg ccaactgaat cgtgggggtga gctttatagc cagtagaggt 1920
ggaggggacc tggcatgtgc caaagaagag gccctctggg tgatgaagtg accatcacat 1980
ttggaaagtg atcaaccact gttccttcta tggggctctt gctctaagt ctatggtgag 2040
aacacaggcc ccgccccttc cctttagtag ccatagaaat attctggctt ggggcagcag 2100
tcccttcttc ccttgatcat ctgcctctgt tcctacactt acgggtgtat ctccaaatcc 2160
tctcccaatt ttattccctt attcatttca agagctccaa tggggctctcc agctgaaagc 2220
ccctccggga ggcagggttg aaggcaggca ccacggcagg tttccgcga tgatgtcacc 2280
tagcagggtc tcagggggtc ccactaggat gcagagatga cctctcgctg cctcacaagc 2340
agtgcacct cgggtccttt ccgttgctat ggtgaaaatt cctggatgga atggatcaca 2400
tgagggtttc ttggtgcttt tggagggtgt gggggatatt ttggttttgt ttttctgcag 2460
gttccatgaa aacagccctt ttccaagccc attgtttctg tcatggtttc catctgtcct 2520
gagcaagtca ttcttttgtt atttagcatt tcgaacatct cggccattca aagcccccac 2580
gttctctgca ctgtttggcc agcataacct ctagcatcga ttcaaagcag agttttaacc 2640
tgacggcatg gaatgtataa atgagggtgg gtccttctgc agatactcta atcactacat 2700
tgctttttct ataaaactac ccataagcct ttaaccttta aagaaaaatg aaaaagggtta 2760
gtgtttgggg gccgggggag gactgaccgc ttcataagcc agtacgtctg agctgagtat 2820
gtttcaataa accttttgat atttctcaaa aaaaaaaaaa aaaaaaaaaa 2870

```

```

<210> 2
<211> 403
<212> PRT
<213> Homo sapiens

```

```

<400> 2
Met Phe Val Ala Ser Glu Arg Lys Met Arg Ala His Gln Val Leu Thr
  1          5          10          15
Phe Leu Leu Leu Phe Val Ile Thr Ser Val Ala Ser Glu Asn Ala Ser
  20          25          30
Thr Ser Arg Gly Cys Gly Leu Asp Leu Leu Pro Gln Tyr Val Ser Leu
  35          40          45
Cys Asp Leu Asp Ala Ile Trp Gly Ile Val Val Glu Ala Val Ala Gly
  50          55          60
Ala Gly Ala Leu Ile Thr Leu Leu Leu Met Leu Ile Leu Leu Val Arg
  65          70          75          80
Leu Pro Phe Ile Lys Glu Lys Glu Lys Lys Ser Pro Val Gly Leu His
  85          90          95
Phe Leu Phe Leu Leu Gly Thr Leu Gly Leu Phe Gly Leu Thr Phe Ala
  100         105         110
Phe Ile Ile Gln Glu Asp Glu Thr Ile Cys Ser Val Arg Arg Phe Leu
  115         120         125
Trp Gly Val Leu Phe Ala Leu Cys Phe Ser Cys Leu Leu Ser Gln Ala
  130         135         140
Trp Arg Val Arg Arg Leu Val Arg His Gly Thr Gly Pro Ala Gly Trp
  145         150         155         160
Gln Leu Val Gly Leu Ala Leu Cys Leu Met Leu Val Gln Val Ile Ile
  165         170         175
Ala Val Glu Trp Leu Val Leu Thr Val Leu Arg Asp Thr Arg Pro Ala
  180         185         190
Cys Ala Tyr Glu Pro Met Asp Phe Val Met Ala Leu Ile Tyr Asp Met
  195         200         205
Val Leu Leu Val Val Thr Leu Gly Leu Ala Leu Phe Thr Leu Cys Gly
  210         215         220
Lys Phe Lys Arg Trp Lys Leu Asn Gly Ala Phe Leu Leu Ile Thr Ala
  225         230         235         240
Phe Leu Ser Val Leu Ile Trp Val Ala Trp Met Thr Met Tyr Leu Phe
  245         250         255
Gly Asn Val Lys Leu Gln Gln Gly Asp Ala Trp Asn Asp Pro Thr Leu
  260         265         270
Ala Ile Thr Leu Ala Ala Ser Gly Trp Val Phe Val Ile Phe His Ala
  275         280         285

```



Ile	Pro	Glu	Ile	His	Cys	Thr	Leu	Leu	Pro	Ala	Leu	Gln	Glu	Asn	Thr
290						295					300				
Pro	Asn	Tyr	Phe	Asp	Thr	Ser	Gln	Pro	Arg	Met	Arg	Glu	Thr	Ala	Phe
305					310					315					320
Glu	Glu	Asp	Val	Gln	Leu	Pro	Arg	Ala	Tyr	Met	Glu	Asn	Lys	Ala	Phe
				325					330					335	
Ser	Met	Asp	Glu	His	Asn	Ala	Ala	Leu	Arg	Thr	Ala	Gly	Phe	Pro	Asn
			340					345					350		
Gly	Ser	Leu	Gly	Lys	Arg	Pro	Ser	Gly	Ser	Leu	Gly	Lys	Arg	Pro	Ser
		355					360					365			
Ala	Pro	Phe	Arg	Ser	Asn	Val	Tyr	Gln	Pro	Thr	Glu	Met	Ala	Val	Val
	370					375					380				
Leu	Asn	Gly	Gly	Thr	Ile	Pro	Thr	Ala	Pro	Pro	Ser	His	Thr	Gly	Arg
385					390					395					400
His	Leu	Trp													

<210> 3  
 <211> 200  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Targeting Vector

<400> 3  
 tga tgc tcat ttc ctagtg agact accct tcat caagga caagg aaagg aagcggcctg 60  
 tgtgcctcca tttcctcttc ctgctgggga ccttgggcct ctttggcctg acgtttgcct 120  
 tcatcatcca gatggacgag acaatctgct ccatccgacg cttcctctgg ggtgtcctct 180  
 tcgcgctctg cttttccgct 200

<210> 4  
 <211> 200  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Targeting Vector

<400> 4  
 gtgagcctgg cactgtgcct gatgctggtg cagg tcatca ttgccactga gtggctggtg 60  
 ctgactgtgc tgcgtgacac gaagccagcc tgcgcctacg agcccatgga ttttgtgatg 120  
 gcgctcatct acgacatggt gctgctggcc atcacctgg ccagtcct cttcacgctg 180  
 tgtggcaagt tcaaacggtg 200